Study on liver dysfunction related to voriconazole by automatic surveillance

doi:10.12092/j.issn.1009-2501.2019.01.008

Abstract

Abstract:

AIM: To study the real-world incidence and related factors of liver dysfunction caused by voriconazole in hospitalized patients. METHODS: The active monitoring system for adverse drug reactions was used to screened inpatients that used voriconazole from January to June 2018 in our hospital. The incidence of liver dysfunction caused by voriconazole was analyzed retrospectively. RESULTS: A total of 251 patients, liver dysfunction rate was 12.35% and mild to moderate liver dysfunction was 87.09%. Spearman correlation coefficients and binary logistic regression analysis showed that the liver dysfunction rate was positively related to voriconazole's trough concentration (P=0.000; P=0.001). The incidence of liver dysfunction was significantly increased (P=0.000) when the plasma trough concentration was greater than 5 mg /L.CONCLUSION: There is a significant correlation between voriconazole's liver dysfunction and trough concentration. In clinical application, it is essential to pay attention to the inpatient whose plasma trough concentration greater than 5 mg/L in order to reduce the risk of liver dysfunction.

Key words: voriconazole, liver dysfunction, active surveillance, safety

CLC Number:

R969.3

ZHAO Quanfeng, FU Peishu, MA Huan, ZHAO Suyu, GUO Daihong, TANG Min. Study on liver dysfunction related to voriconazole by automatic surveillance[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(1): 43-48.

References

［1］冯飞飞, 张晓云, 任秋霞, 等. 伏立康唑致精神、视觉障碍和肝功能损害1例［J］. 中国药物应用与监测, 2017, 14(2): 128-129.
［2］李双, 李华彬, 李洪磊, 等. 伏立康唑致急性肝衰竭1例［J］. 中国感染控制杂志, 2018, 17(2): 172-174.
［3］白艳, 李悦, 刘斌, 等. 抗真菌药肝毒性的文献计量学分析［J］. 药物不良反应杂志, 2014, 16(3): 134-138.
［4］耿维, 张宏, 李成建. 伏立康唑所致肝损害文献概述［J］. 中国药物滥用防治杂志, 2016, 22(6): 361.
［5］国家食品药品监督管理局药品安全监管司，国家药品不良反应中心编. 药品不良反应报告和监测工作手册［S］. 2005: 46.
［6］于乐成, 茅益民, 陈成伟. 药物性肝损伤诊治指南［J］. 临床肝胆病杂志, 2015, 31(11): 1752-1769.
［7］王陶陶, 陈思颖, 尤海生, 等. 侵袭性真菌感染患者伏立康唑肝毒性的研究［J］. 中国药学杂志, 2018, 53(4): 290-294.
［8］Ping B, Zhu Y, Gao Y, et al. Second-versus first-generation azoles for antifungal prophylaxis in hematology patients: a systematic review and meta analysis ［J］. Ann Hematol, 2013, 92(6): 831-839.
［9］Lamoureux F, Duflot T, Woillard JB, et al. Impact of CYP2C19 genetic polymorphisms on voriconazole dosing and exposure inadult patients with invasive fungal infections［J］. Int J Antimicrob Agents, 2016, 47(2): 124-131.
［10］Pessayre D, Fromenty B, Berson A, et al. Central role of mitochondria in drug-induced liver injury［J］. Drug Metab Rev, 2012, 44(1): 34-87.
［11］张弨. 伏立康唑的药效学研究评价［J］. 中国临床药理学与治疗学, 2018, 23(1): 116-120.
［12］魏栋, 张耀文, 陆文岐, 等. 伏立康唑用药安全性的评价［J］. 中国临床药理学杂志, 2017, 33(20): 2077-2080.
［13］Denning DW, Cadranel J, Beigelman-Aubry C, et al. Chronic pulmonary aspergillosis: rationale and clinical guidelines for diagnosis and management ［J］. Eur Respir J, 2016, 47(1): 45-68.
［14］Patterson TF, Thompson GR, Denning DW, et al. Practice guidelines for the diagnosis and management of aspergillosis: 2016 Updateby the Infectious Diseases Society of America ［J］. Clin Infect Dis. 2016, 63(4): e1-e60.
［15］中华医学会器官移植学分会, 中国医师协会器官移植医师分会.中国实体器官移植受者侵袭性真菌病临床诊治指南(2016年版)［J］. 中华器官移植杂志, 2016, 37(5): 300-305.
［16］Kim SH, Yim DS, Choi SM, et al. Voriconazole-related severe adverse events: clinical application of therapeutic drug monitoring in Korean patients［J］. Int J Infect Dis, 2011, 15(11): e753-758.
［17］Wang TT, Zhu HF, Sun JY, et al. Efficacy and safety of voriconazole and CYP2C19 polymorphism for optimised dosage regimens in patients with invasive fungal infections［J］. Int J Antimicrob Agents, 2014, 44(5): 436-442.
［18］Jin H, Wang T, Folcione BA, et al. Trough concentration of voriconazole and its relationship with efficacy and safety: a systematic review and meta-analysis［J］. J Antimicrob Chemother, 2016, 71(7): 1772-1785.
［19］Imataki O, Yamaguchi K, Uemura M, et al. Voriconazole concentration is inversely correlated with corticosteroid usage in immunocompromised patients［J］. Transpl Infect Dis, 2018, 20(4): e12886.
［20］Luong ML, Al-Dabbagh M, Groll AH, et al. Utility of voriconazole therapeutic drug monitoring: a meta-analysis ［J］. J Antimicrob Chemother, 2016, 71(7): 1786-1799.
［21］Pascual A, Calandra T, Bolay S, et al. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes ［J］. Clin Infect Dis, 2008, 46(2): 201-211.

[1]	XIAO Yue, LI Tangfei, XUE Qianfu. Analysis of the efficacy and safety of Peg-IFN-α in the treatment of essential thrombocythemia [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(9): 1049-1055.
[2]	JIA Boying, ZHOU Shuang, WAN Liyan, ZHOU Ying, CUI Yimin. Drug-induced dysphagia risk in elder people——A pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) database [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(10): 1109-1120.
[3]	LIU Min, KONG Xiang, ZHANG Ye, GU Yifei, XIANG Xuemei, HUANG Kai. Safety analysis on bioequivalence studies of orally inhaled drug products in healthy Chinese subjects#br# [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(10): 1131-1138.
[4]	LIANG Meifang, CHEN Qingzhuang, YANG Peiqun, WANG Yong. Efficacy and safety of generic and branded atorvastatin in patients with ischemic stroke/transient ischemic attack: A real-world study [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(7): 785-792.
[5]	BAO Jing, CHEN Xiaowen, XIA Liang, ZHAO Yuchen, XIA Ruixiang, XIA Hailong. Clinical efficacy and safety of ixazomib in the treatment of multiple myeloma [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(7): 782-786.
[6]	PENG Min, HUANG Panhao, DENG Yinhua, LIU Wen, LI Wei, YU Zhen, XIA Qing, XIE Yueliang. Analysis of influence factors of voriconazole trough concentration in patients with hematopoietic stem cell transplantation [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(6): 640-646.
[7]	GUO Mingxing, GUO Heng, SHEN Su, SUN Liying, CUI Xiangli. Retrospective analysis of voriconazole in the monitoring of therapeutic drugs in patients with liver dysfunction [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(7): 757-763.
[8]	PAN Luping, SHI Wujie, SHEN Zhipeng. Efficacy and safety of etoposide combined with carboplatin in children with recurrent medulloblastoma [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(2): 189-195.
[9]	SHI Lili, LIU Xingan, SHAN Guoyong. Efficacy and safety of apatinib in the further line treatment for patients with advanced colorectal cancer failed after standard therapy and the preliminary analysis of efficacy predictors [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(12): 1388-1394.
[10]	YANG Haijing, YU Jicheng, WANG Jingjing, LI Nanyang, WU Jufang, ZHANG Hai, XUE Tao, DAI Weiguo, DING Tianling, CAO Guoying. Risk management of biological agents in phase I clinical trials: Case sharing [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(1): 44-48.
[11]	LIU Simin, CAI Jun, LI Huixin, YANG Li, ZHAO Yan, ZHANG Jinping. Research progress in population pharmacokinetics of voriconazole in adults [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(9): 1015-1023.
[12]	HUA Xudan, XIE Hongyi, YU Shufang. Analysis of the efficacy, safety and economics of prophylactic antibiotics in high-risk neonates guided by C reaction protein and procalcitonin [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(5): 561-566.
[13]	WANG Haili, GONG Tianxiao, ZHOU Shixia, MEI Jiazhuan, ZHANG Zhongmian. Efficacy and safety of third-line treatment with mesylate apatinib in patients with advanced non-small cell lung cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(5): 567-572.
[14]	KANG Hui, YONG Xiaolan, HU Tingting, CHU Bixin, WANG Lantian. Pharmacokinetic study and safety assessment of lacosamide tablets in Chinese healthy subjects under fasting condition [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(2): 192-197.
[15]	YANG Ke, LI Junling, DU Bin, TIAN Zhongqiu, JING Xiujuan. Single-arm,one-center, exploratory clinical trial of albumin-bound paclitaxel second and more line therapy for advanced non-small cell lung cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(11): 1281-1286.